Tag Archives: Biotechnology and Pharmaceuticals

Upcoming Webcast: The Visibility Solution

By George Koroneos | Published: March 15, 2010
The Visibility Solution: Delivering an Accurate View of Clinical Operations Thursday, April 1, 2010 at 11:00 AM PT; 2:00 PM ET; 16:00 GMT This event focuses on our Clinical Trials solution with HighPoint Solutions and is designed to illustrate how pharma companies can reduce the risk and expense of the clinical trial process with better use of [...]
Posted in Webcast | Also tagged , , , , , , | Leave a comment

The Case for Specialty Medicines: Is Industry Credible, or Culpable?

By William Looney | Published: November 11, 2009
What’s so special about specialty? This was the question lurking below the surface in many of the presentations at a conference hosted by Pharm Exec’s sister organization, CBI, in Philadelphia last week. Now that the blockbuster era is fading under a wave of patent expirations, big pharma is pinning its hopes on the specialty category [...]
Posted in Strategy | Also tagged , , , , , , | Leave a comment

A Lead Drug on the Way? All Eyes on FDA

By Brittany Agro | Published: November 4, 2009
For NeurogesX, a small biopharma company based in San Mateo, CA, time does not stand still. Every day preceding November 16 brings its flagship drug, Qutenza, one step closer to approval. Until then, the company has turned its energies to finalizing its US commercialization strategy. (NeurogesX previously entered into a commercialization agreement with Astellas Pharma [...]
Posted in Strategy | Also tagged , , , | Leave a comment

Abbott to Purchase Solvay for $6.6 Billion (Update 1)

By George Koroneos | Published: September 28, 2009
Abbott announced, early Monday morning, that it had signed a deal to purchase Belgium-based drug manufacturer Solvay Pharmaceuticals for $6.6 billion in cash—a mere five months after Solvay’s CEO Werner Cautreels announced that the company was searching for a proper suitor. The deal adds more than $3 billion in annualized sales to its global pharmaceutical business—three-quarters [...]
Posted in Strategy | Also tagged , , , , , , | Leave a comment

Q&A with Steven Paul: Lilly’s New Development Plan

By George Koroneos | Published: September 23, 2009
Last week, Lilly announced a major restructuring plan focused around the creation of one Developmental Center of Excellence and several individual business units. The media (Pharm Exec included) focused on the news that 5,500 jobs were being cut as part of the plan. This week, we’re talking to Lilly to find out what the company’s [...]
Posted in Strategy | Also tagged , , , , , , | 3 Comments